Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The product of HFE2 is involved in iron metabolism. Additionally we are shipping HFE2 Kits (32) and HFE2 Proteins (13) and many more products for this protein.
Showing 10 out of 97 products:
Human Polyclonal HFE2 Primary Antibody for EIA, FACS - ABIN952726
Zhang, Yang, Wang, Tsukamoto, Enns: Hemojuvelin-neogenin interaction is required for bone morphogenic protein-4-induced hepcidin expression. in The Journal of biological chemistry 2009
Show all 3 references for ABIN952726
Human Polyclonal HFE2 Primary Antibody for IHC (p), WB - ABIN952727
Zhu, Feng, Li, Lu, Elston: Detecting rare variants for complex traits using family and unrelated data. in Genetic epidemiology 2010
Show all 3 references for ABIN952727
Human Polyclonal HFE2 Primary Antibody for ELISA, WB - ABIN566853
Lakhal, Schödel, Townsend, Pugh, Ratcliffe, Mole: Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. in The Journal of biological chemistry 2011
study shows that patients with CRA (show MTMR11 Antibodies) had high expression of BMP6 (show BMP6 Antibodies) and hepcidin (show HAMP Antibodies) and low expression of s-HJV. BMP6 (show BMP6 Antibodies) was found to be negatively correlated with s-HJV; both regulate hepcidin (show HAMP Antibodies) expression and play important roles in the development of anemia.
HJV levels are low in NAFLD (show TSC2 Antibodies) and even lower in iron overloaded NAFLD (show TSC2 Antibodies).
Data show that transmembrane serine protease (show F2 Antibodies) TMPRSS6 (show TMPRSS6 Antibodies) cleaves both the heterodimeric and the full-length mutant hemojuvelin (m-HJV).
Hereditary haemochromatosis caused by homozygous HJV mutation evolved through paternal disomy.
The study demonstrates that the two upstream open reading frames (with 28 and 19 codons) present in the 5' UTR (show UTS2R Antibodies) of the human HJV mRNA have the ability to significantly decrease translational efficiency under normal conditions.
Case Reports: juvenile hemochromatosis (show HFE Antibodies) associated with simple heterozygosity for novel HJV mutations and unknown genetic factors.
suggesting that the homozygous mutation p.C321X in HJV is causative in the patient with hemochromatosis (show HFE Antibodies)
In dialysis patients, hemojuvelin levels are significantly increased but obesity does not have an additional impact.
Membrane bound hemojuvelin (HJV) is associated with decreasing total kidney iron, secreting hepcidin (show HAMP Antibodies), and promoting the degradation of ferroportin (show SLC40A1 Antibodies) during acute kidney injury, whereas soluble HJV does the opposite.
Data show that Patients with iron-refractory iron-deficiency anemia with a mutation in the TMPRSS6 (show TMPRSS6 Antibodies) gene were found to have lower levels of circulating hemojuvelin than those in healthy patients.
Results indicate that an efficient induction of hepcidin (show HAMP Antibodies) expression by hemojuvelin (HJV) requires its interaction with neogenin (show NEO1 Antibodies).
Single Hjv(-)/(-) and double Hfe (show HFE Antibodies)(-)/(-)Hjv(-)/(-) mice exhibit comparable iron overload. Hfe (show HFE Antibodies) and Hjv regulate hepcidin (show HAMP Antibodies) via the same pathway.
Results show that HFE (show HFE Antibodies) may depend on HJV for hepcidin (show HAMP Antibodies) regulation. Residual hepcidin (show HAMP Antibodies) in the absence of HFE (show HFE Antibodies) suggests either the presence of an unknown regulator synergistic with HJV or that HJV is sufficient to maintain basal levels of hepcidin (show HAMP Antibodies).
Parenchymal hepatic iron overload does not suffice to trigger progression of liver steatosis to steatohepatitis or fibrosis in Hjv knockout C57BL/6 mice.
Hjv is not required for sensing of body iron levels and merely functions as an enhancer for iron signaling to hepcidin (show HAMP Antibodies).
Deletion of Hjv in mice leads to abnormal retinal angiogenesis/vasculogenesis, with proliferation of new, leaky blood vessels in the vitreous.
Loss of matriptase-2 (show TMPRSS6 Antibodies) increases bone morphogenetic protein-dependent signaling, while paradoxically decreasing liver hemojuvelin protein content.
Use of proteomic analysis enables identification of four disulfide linkages in hemojuvelin/repulsive guidance molecule C. This molecule is a single-chain HJV/RGMc isoform.
we conclude that TNF-alpha (show TNF Antibodies) suppresses Hemojuvelin(HJV) transcription possibly via a novel TNFRE within the HJV promoter
high levels of serum s-HJV in CDA I patients, suggesting that it may contribute to iron loading pathology in CDA I and eventually in other anemias with ineffective erythropoiesis.
The product of this gene is involved in iron metabolism. It may be a component of the signaling pathway which activates hepcidin or it may act as a modulator of hepcidin expression. It could also represent the cellular receptor for hepcidin. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene. Defects in this gene are the cause of hemochromatosis type 2A, also called juvenile hemochromatosis (JH). JH is an early-onset autosomal recessive disorder due to severe iron overload resulting in hypogonadotrophic hypogonadism, hepatic fibrosis or cirrhosis and cardiomyopathy, occurring typically before age of 30.
hemochromatosis type 2 (juvenile)
, RGM domain family member C
, hemochromatosis type 2 protein
, repulsive guidance molecule c
, hemochromatosis type 2 (juvenile) (human homolog)
, hemochromatosis type 2 protein homolog
, repulsive guidance molecule C